Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY2018 Earnings Presentation
12 slides from Alkem Laboratories's earnings presentation, May 30, 2018
Slide 1: Investor Presentation Q4FY18 – May 30, 2018
Investor Presentation Q4FY18 – May 30, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights For Q4FY18 and FY18
Key Highlights For Q4FY18 and FY18 Healthy revenue growth in key markets of India and US • India Business – double digit underlying growth: Adjusted for the GST impact, the India business grew in double digit for the quarter and year ended March 31, 2018. As per IMS data, the Company outperformed th
Slide 4: Key Financial Highlights – Q4FY18 (Consolidated)
Key Financial Highlights – Q4FY18 (Consolidated) All figures in Rs mn Total Revenue from Operations India sales 9,602 15,132 8,563 Adjusting for the impact of GST, YoY growth was even 12,514 higher Q4FY17 Q4FY18 International sales 5,236 3,853 Q4FY17 Q4FY18 Notes: Post implementation of GST with eff
Slide 5: Key Financial Highlights – Q4FY18 (Consolidated)
Key Financial Highlights – Q4FY18 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin Other Expenses for Q4FY18 and FY18 8,972 1,493 includes net loss on fair 7,906 valuation of current 1,138 investments (Please refer our press release for details) 63.2% 59.3%
Slide 6: Key Financial Highlights – FY18 (Consolidated)
Key Financial Highlights – FY18 (Consolidated) Particulars (Rs mn) FY18 FY17 YoY growth Revenue from Operations 64,312 58,525 9.9% Gross Profit 39,183 36,310 7.9% Gross Profit margin 60.9% 62.0% EBITDA 10,284 9,990 2.9% EBITDA margin 16.0% 17.1% PBT 9,260 9,646 (4.0)% PBT margin 14.4% 16.5% PAT (Aft
Slide 7: India Business
India Business India Business: Q4FY18 Sales of Rs.9,602 million (12.1% growth YoY) • India sales contributed 64.7% to total sales in Q4FY18 • Adjusting for the GST impact, YoY growth during the quarter and year ending March 31, 2018 was even higher • During the quarter and year ended March 31, 2018,
Slide 8: India Business – Secondary Sales Performance
India Business – Secondary Sales Performance Outperformance across all the major therapeutic areas in FY18 Established therapeutic +1 Market rank 1 3 3 4 areas of Alkem 10.6% 11.5% 6.6% 6.0% 5.3% 2.7% 3.5% 1.5% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alkem s
Slide 9: US Business
US Business US Business: Q4FY18 Sales of Rs.4,071 million (40.0% growth YoY) • US sales contributed 27.4% to total sales in Q4FY18 • In FY18, US revenues crossed US$200mn • In Q4FY18, the Company filed 11 ANDAs with the US FDA and received 1 approval • As on March 31, 2018, the Company has filed a t
Slide 10: Other International Business
Other International Business Other International Business: Q4FY18 Sales of Rs.1,165 million (23.2% growth YoY) • Other International Market sales contributed 7.9% to total sales in Q4FY18 • Company’s key markets including Australia, Philippines, Chile and Kazakhstan recorded healthy growth for the q
Slide 11: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on March 31, 2018 Non-Institution, 27.22% Promoter & Promoter Group, Institution, 65.86% 6.92% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodie
Slide 12: Thank You
Thank You